Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07149363

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

Led by Alliance Foundation Trials, LLC. · Updated on 2026-02-17

65

Participants Needed

1

Research Sites

260 weeks

Total Duration

On this page

Sponsors

A

Alliance Foundation Trials, LLC.

Lead Sponsor

A

AstraZeneca

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).

CONDITIONS

Official Title

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Body weight greater than 30 kg
  • Life expectancy of at least 12 weeks
  • Confirmed diagnosis of pathologic T1-T2 N0-1 M0 small-cell lung cancer
  • Complete surgical removal of small-cell lung cancer within 78 days prior to enrollment
  • Complete mediastinal lymph node dissection or systematic sampling performed
  • No prior systemic therapy for small cell lung cancer
  • Post-operative radiation allowed for N1 disease as per physician
  • ECOG performance status of 0 or 1
Not Eligible

You will not qualify if you...

  • Receiving any other investigational agents
  • Enrolled in another clinical study with investigational treatment for small cell lung cancer
  • Prior treatment with durvalumab
  • History of another primary cancer except certain treated low-risk cancers without active disease for at least 2 years
  • History of cerebrovascular accident, pulmonary embolism, or untreated deep venous thrombosis within past 3 months
  • Hemoptysis exceeding 2.5 mL within 2 weeks before first study treatment
  • Need for concurrent treatment with phenytoin, phenobarbital, or carbamazepine

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Virginia Comprehensive Cancer Center

Charlottesville, Virginia, United States, 22908

Actively Recruiting

Loading map...

Research Team

Q

Quality Management and Compliance

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here